Latest news
Tasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platforms - Manufacturing ChemistManufacturing Chemist · Tue, 04 Aug 2026 12:14:55 GMTTasrif secures second US patent for CD155-targeting antibodies as anti-TIGIT field contracts - AllSciAllSci · Wed, 29 Jul 2026 14:10:13 GMTTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155) - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMT